Background: Omalizumab has demonstrated therapeutic benefits both in controlled clinical
trials and real-life studies. However, research concerning the long-term effects and …

Introduction Allergic asthma is a chronic inflammatory disease caused by immunoglobulin E
(IgE)-mediated allergy. Omalizumab is a monoclonal anti-IgE antibody for the treatment of …

Omalizumab is frequently used as add-on treatment to inhaled corticosteroids (ICS) and
long-acting β2-agonists in patients with suboptimal control of severe asthma. Patients with …

Introduction: Efficacy and safety of omalizumab in patients with severe allergic asthma has
been established in both randomized controlled trials and real-life studies Aim: To evaluate …

Objective: To evaluate the long-term efficacy and safety of omalizumab in asthma in a real-
life setting. Subjects and Methods: This 4-year observational study included 65 patients …

Background. Asthma guidelines emphasize the importance of achieving and maintaining
asthma control; however, many patients with moderate to severe asthma fail to achieve …

Background Omalizumab was introduced in Malta in 2011. To date, no local data have been
published. Objective To obtain baseline characteristics of our local cohort, determine …

Omalizumab (Xolair®) is a humanized monoclonal antibody used in the treatment of
adolescent and adult patients with moderate to severe allergic asthma inadequately …

The ability of omalizumab, an anti-immnoglobulin‐E agent, to maintain long‐term disease
control in patients with moderate-to-severe allergic asthma was investigated in a 24‐week …

Abstract Background Randomized Controlled Trials showed that omalizumab exhibited a
good safety and tolerability profile in patients with moderate-to-severe asthma. However …